Neurology clinical trial failures

Phase II Alzheimer Disease trial by Merck Sharp & Dohme LLC. Stop reason: OTHER/UNKNOWN.

Termination Notes: Business reason

Phase IV Drug-resistant Focal Seizure trial by Beth Israel Deaconess Medical Center. Stop reason: OPERATIONAL.

Failure to recruit subjects.

Phase III Migraine trial by Eli Lilly and Company. Stop reason: OPERATIONAL.

Study terminated due to strategic business decision

Phase I Relapsing Multiple Sclerosis (RMS) trial by Cabaletta Bio. Stop reason: OPERATIONAL.

The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.

Phase III Early Alzheimer's Disease trial by Alzheon Inc.. Stop reason: OPERATIONAL.

Sponsor business decision

Phase III Agitation in Patients With Dementia of the Alzheimer's Type trial by Axsome Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.

Study AXS-05-AD-305 was terminated due to completion of overall program objectives.

Unknown Sialorrhea True Bulbar Palsy Medullary Injury trial by houyajing. Stop reason: OTHER/UNKNOWN.

In accordance with the time-limit regulations for ethical review, since the ethical approval certificate of this study protocol has expired, I hereby formally apply for the withdrawal of this study from the clinical trial registration platform.

Phase I Multiple Sclerosis (MS) trial by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Stop reason: OTHER/UNKNOWN.

Legend discontinues the development of the IMP.

Phase IV Transformed Migraine trial by Rutgers, The State University of New Jersey. Stop reason: OPERATIONAL.

no patients during covid pandemic

Phase I GBA1 Parkinson Disease trial by Capsida Biotherapeutics, Inc.. Stop reason: OTHER/UNKNOWN.

Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.

Phase III Impulse Control Disorder trial by Centre Hospitalier Universitaire, Amiens. Stop reason: OTHER/UNKNOWN.

Zambon corparate has decided not to renew the production of the samples.

Phase I Developmental and Epileptic Encephalopathy trial by Capsida Biotherapeutics, Inc.. Stop reason: OTHER/UNKNOWN.

Stopping rule for study was met

Unknown Migraine trial by W.L.Gore & Associates. Stop reason: OPERATIONAL.

Dissatisfactory enrollment rate with no safety concerns

Phase III Pain Due to Certain Specified Procedures trial by University Hospital, Limoges. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

Phase II Dementia With Lewy Bodies trial by Georgetown University. Stop reason: EFFICACY/FUTILITY.

Interim analysis was performed for 442 patients who completed Part I of the PROSEEK study-(CLR\_18\_06); it did not show evidence of treatment benefit in patients receiving Vodobatinib.

Phase II Agitation trial by BioXcel Therapeutics Inc. Stop reason: OPERATIONAL.

Study was terminated for business reasons; not due to safety or efficacy concerns

Phase II Lung Cancer trial by Sound Pharmaceuticals, Incorporated. Stop reason: OTHER/UNKNOWN.

Study did not start

Phase I Fibromyalgia trial by University of Alabama at Birmingham. Stop reason: OPERATIONAL.

Lost funding.

Phase II Spasticity trial by Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC. Stop reason: OPERATIONAL.

Company/sponsor business decision; not due to or related to any safety concerns

Phase II SCN8A Developmental and Epileptic Encephalopathy Syndrome trial by Neurocrine Biosciences. Stop reason: OPERATIONAL.

This study was prematurely terminated due to sponsor decision.

Phase III ALS trial by Tanabe Pharma America, Inc.. Stop reason: EFFICACY/FUTILITY.

Futility was met.

Phase III ALS trial by Tanabe Pharma America, Inc.. Stop reason: EFFICACY/FUTILITY.

Futility Analysis of parent study MT-1186-A02 was met.

Phase II Oxaliplatin-induced Peripheral Neuropathy trial by UNICANCER. Stop reason: OPERATIONAL.

Lack of treatment, sponsor decision.

Phase II Alzheimer's Disease trial by Botanicure Co., Ltd.. Stop reason: OTHER/UNKNOWN.

The study was withdrawn before participants were enrolled.

Phase II Neuropathic Pain trial by Virginia Commonwealth University. Stop reason: OPERATIONAL.

Insufficient staffing

Phase II Fibromyalgia trial by University of Chicago. Stop reason: OTHER/UNKNOWN.

PI has left university

Phase III Amyotrophic Lateral Sclerosis trial by Stichting TRICALS Foundation. Stop reason: EFFICACY/FUTILITY.

The planned interim analysis showed no survival benefit of taking the drug when compared with placebo.

Phase II Alzheimer's Disease trial by Shanghai Hengrui Pharmaceutical Co., Ltd.. Stop reason: OTHER/UNKNOWN.

Based on the adjustment of the sponsor's R\&D strategy, it is decided to terminate this study in advance.

Phase III Progressive Multiple Sclerosis trial by AB Science. Stop reason: OTHER/UNKNOWN.

The study has been suspended but may start again in the future.

Phase III Multiple Sclerosis trial by Amsterdam UMC, location VUmc. Stop reason: EFFICACY/FUTILITY.

In line with the study protocol, due to slow recruitment, a futility analysis has been performed in the first quarter of 2025 by an independent statistician. The result of the analysis was restricted to a "no-go".

Phase II Alzheimer's Disease trial by TrueBinding, Inc.. Stop reason: OTHER/UNKNOWN.

Resource Constraints

Phase II Amyotrophic Lateral Sclerosis trial by Implicit Bioscience. Stop reason: OPERATIONAL.

No participants enrolled in study

Phase I Alzheimer Disease trial by University Hospital, Lille. Stop reason: OPERATIONAL.

sponsor decision

Phase II Amyotrophic Lateral Sclerosis trial by Implicit Bioscience. Stop reason: OPERATIONAL.

No enrollment

Phase I Alzheimer Disease trial by Alzheimer's Disease Expert Lab (ADEL), Inc.. Stop reason: OPERATIONAL.

Study discontinued due to sponsor transition and strategic decision not to continue the protocol.

Phase IV Migraine Headaches trial by Icahn School of Medicine at Mount Sinai. Stop reason: OTHER/UNKNOWN.

Study closing at current site. Study to start as new at different site.

Phase II Neuromyelitis Optica trial by Xuanwu Hospital, Beijing. Stop reason: OPERATIONAL.

Difficult in participant recruiting

Phase II Primary Progressive Multiple Sclerosis trial by Mapi Pharma Ltd.. Stop reason: OTHER/UNKNOWN.

The study was terminated early as part of a global realignment of Sponsor's clinical development programs. This decision is not related to any safety concerns regarding the IP.

Phase I Parkinson Disease trial by InnoMedica Schweiz AG. Stop reason: OTHER/UNKNOWN.

Treatment stopped earlier due to Verfügung Swissmedic. Safety visits in the end of the trial still were carried out (LPLV 06.08.2025).

Phase II Amyotrophic Lateral Sclerosis trial by Revalesio Corporation. Stop reason: OTHER/UNKNOWN.

Withdrawn prior to initiation

Phase II Multiple Sclerosis, Relapsing-Remitting trial by RemeGen Co., Ltd.. Stop reason: OPERATIONAL.

Sponsor Strategic Priority Adjustment

Phase III Neuromyelitis Optica Spectrum Disorders trial by RemeGen Co., Ltd.. Stop reason: OPERATIONAL.

Sponsor Strategic Priority Adjustment

Phase II Alzheimer Disease trial by NeuroSense Therapeutics Ltd.. Stop reason: OTHER/UNKNOWN.

Company will improve study desig

Phase II Alzheimer Disease trial by Janssen Research & Development, LLC. Stop reason: OTHER/UNKNOWN.

Posdinemab did not achieve statistical significance in slowing clinical decline

Phase II Parkinson's Disease trial by UCB Biopharma SRL. Stop reason: OTHER/UNKNOWN.

Based on available data, the decision was made to stop development of UCB0599/minzasolmin as treatment of Parkinson's Disease.

Phase I Multiple Sclerosis trial by Robert Fox. Stop reason: OPERATIONAL.

Sponsor terminated funding.

Phase II Mitochondrial Diseases trial by PTC Therapeutics. Stop reason: OPERATIONAL.

Sponsor decision.

Early Phase I Vestibular Migraine trial by Vanderbilt University Medical Center. Stop reason: OPERATIONAL.

Unable to gain interest among colleagues to help recruit participants.

Early Phase I Multiple Sclerosis trial by Huashan Hospital. Stop reason: OPERATIONAL.

Due to the sponsor's adjustment of the research and development strategy for this clinical trial, this study was prematurely terminated, and no subjects were recruited for this study.

Phase II Generalized Epilepsy trial by Biohaven Therapeutics Ltd.. Stop reason: OPERATIONAL.

Sponsor Decision

Phase II Transcranial Direct Current Stimulation trial by Chang Gung Memorial Hospital. Stop reason: OPERATIONAL.

The trial was suspended due to the budget issue

Phase II Epilepsy trial by Takeda. Stop reason: OPERATIONAL.

Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-18-001 study is no longer necessary. Therefore, Takeda has made a decision to close this study

Phase II Migraine trial by University of California, San Diego. Stop reason: OPERATIONAL.

Inadequate funding

Phase I Alzheimer Dementia trial by University of Arizona. Stop reason: OPERATIONAL.

Study interrupted by COVID-19 pandemic and could not be restarted at current location. Study investigators determined that relocating and continuing the study under its original scope was not feasible given preliminary results from IM injections.

Phase IV Idiopathic Parkinson's Disease (at Later Stage) trial by Alain Kaelin. Stop reason: OPERATIONAL.

insufficient eligible patients for enrollment

Phase I Parkinson Disease trial by University of Arkansas. Stop reason: OPERATIONAL.

project not funded

Phase II Apathy in Dementia trial by AbbVie. Stop reason: OPERATIONAL.

Sponsor Decision - Not Safety Related

Phase III Migraine trial by Eli Lilly and Company. Stop reason: OPERATIONAL.

Study terminated due to strategic business decision

Phase I Neuroblastoma trial by Yael P Mosse. Stop reason: OTHER/UNKNOWN.

The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular aberrations made Part 2 (treatment) no longer feasible.

Phase II Neuroendocrine Tumors trial by Antonio Fojo. Stop reason: OPERATIONAL.

Lack of funding and drug supply

Phase IV Migraine Disorders trial by Beth Israel Deaconess Medical Center. Stop reason: OPERATIONAL.

poor enrollment

Phase II Alzheimer Disease trial by Inmune Bio, Inc.. Stop reason: OTHER/UNKNOWN.

Sponsor resource allocation

Phase II Alzheimer's Disease trial by Alector Inc.. Stop reason: EFFICACY/FUTILITY.

Parent study failed to meet the primary endpoint and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints.

Phase I Alzheimer Disease trial by Ionis Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.

Sponsor decision to terminate study early. Decision not based on safety concerns.

Phase II Epileptic Encephalopathy trial by Neurocrine Biosciences. Stop reason: OPERATIONAL.

Business decision

Phase I Multiple Sclerosis, Progressive trial by Wake Forest University Health Sciences. Stop reason: OPERATIONAL.

lack of funding

Phase I Relapsing Remitting Multiple Sclerosis trial by Jeffrey Gelfand. Stop reason: OPERATIONAL.

Under-enrollment, including after interruption due to a hold on source FMT material and the COVID-19 pandemic

Phase III Cerebral Palsy trial by Hospices Civils de Lyon. Stop reason: OPERATIONAL.

The Steering Committee decided on 22/09/2025 to end the project, due to persistent issues: enrolment suspended because of supply shortages and the arrival of alternative treatments, as well as the end of a key supply agreement.

Phase IV Migraine Disorders trial by Supernus Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.

Difficulty in recruitment

Phase III Frontotemporal Dementia trial by Alector Inc.. Stop reason: EFFICACY/FUTILITY.

The trial did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR® plus NACC FTLD-SB)

Phase III Neurodegenerative Diseases trial by Alector Inc.. Stop reason: EFFICACY/FUTILITY.

The AL001-CS-302 study was terminated because its Phase 3 placebo-controlled parent study (AL001-3) failed to meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating® plus National Alzheimer's

Phase II Headache, Migraine trial by Washington University School of Medicine. Stop reason: OPERATIONAL.

The eligibility criteria within the protocol led to the exclusion of a large proportion of potential participants, thereby limiting enrollment. During the conceptualization phase, the number of eligible patients was overestimated.

Phase I Diabetic Neuropathy Peripheral trial by University of Maryland, Baltimore. Stop reason: OPERATIONAL.

Completed the pilot study and grant funding not obtained to continue to the main phase 2 study. The pilot study did not show a statistical significance in the primary or secondary outcome measures.

Phase II Amyotrophic Lateral Sclerosis trial by New England Cell Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.

organizational restructure

Phase II Alzheimer's Disease trial by Spinogenix. Stop reason: OTHER/UNKNOWN.

patients treated on compassionate use program

Phase III Painful Diabetic Peripheral Neuropathy (PDPN) trial by Eurofarma Laboratorios S.A.. Stop reason: OTHER/UNKNOWN.

Strategic change in development priorities

Phase II Amyotrophic Lateral Sclerosis (ALS) trial by Spinogenix. Stop reason: OTHER/UNKNOWN.

patients treated through compassionate use program

Phase II Diabetic Peripheral Neuropathic Pain trial by Reata, a wholly owned subsidiary of Biogen. Stop reason: OPERATIONAL.

Sponsor decision to close study early; not due to safety concerns.

Phase I Amyotrophic Lateral Sclerosis trial by Verge Genomics. Stop reason: OPERATIONAL.

Study terminated by Sponsor due to lack of risk-benefit data.

Phase II Alzheimer Disease trial by Vivoryon Therapeutics N.V.. Stop reason: OPERATIONAL.

It has been made the strategic decision to terminate the study. This decision to terminate the study early is not being made for safety reasons.

Phase II Seizures trial by AbbVie. Stop reason: EFFICACY/FUTILITY.

Closed early after CVL-865-SZ-001 (NCT04244175) did not meet its primary objective

Phase III Episodic Migraine trial by AbbVie. Stop reason: EFFICACY/FUTILITY.

The study was terminated early due to lack of efficacy from the primary analysis results.

Phase II Migraine trial by Allodynic Therapeutics, Inc. Stop reason: OPERATIONAL.

No participants enrolled; study suspended due to recruitment challenges.

Early Phase I Vestibular Schwannoma trial by Massachusetts Eye and Ear Infirmary. Stop reason: OPERATIONAL.

Drug manufacturing logistics; lack of access to drug supply

Phase II Alzheimer Disease trial by reMYND. Stop reason: OTHER/UNKNOWN.

Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.

Phase II Painful Diabetic Neuropathy trial by Brigham and Women's Hospital. Stop reason: OTHER/UNKNOWN.

This study never left the planning stages: there was no IRB application and no participants were enrolled.

Phase III Multiple Sclerosis trial by Genzyme, a Sanofi Company. Stop reason: OPERATIONAL.

Enrolment formally closed earlier than planned due to recruitment challenges.

Phase III Multiple Sclerosis, Relapsing-Remitting trial by Biogen. Stop reason: OPERATIONAL.

Due to sponsor decision, not for efficacy or safety reasons.

Phase II Acute Migraine trial by Kallyope Inc.. Stop reason: EFFICACY/FUTILITY.

Study stopped for futility based on an interim analysis of efficacy.

Phase I Tuberous Sclerosis Complex (TSC) trial by GRIN Therapeutics, Inc.. Stop reason: OTHER/UNKNOWN.

Study was terminated due to the lack of operational capabilities of the sites to segregate participants as needed.

Phase II High-grade Extra Pulmonary Neuroendocrine Cancer trial by Baylor Research Institute. Stop reason: OPERATIONAL.

Study halted due to low enrollment

Phase III Seizure in Participants With Tuberous Sclerosis Complex trial by Jazz Pharmaceuticals. Stop reason: OPERATIONAL.

The study was terminated by the Sponsor due to low patient enrollment.

Phase I Parkinson Disease trial by Ventus Therapeutics U.S., Inc.. Stop reason: OPERATIONAL.

Sponsor decision

Phase II Parkinson Disease trial by Alexza Pharmaceuticals, Inc.. Stop reason: OPERATIONAL.

Administrative decision

Phase I Multiple Sclerosis trial by Brigham and Women's Hospital. Stop reason: OPERATIONAL.

The study was terminated without recruitment.

Phase II Mild Cognitive Impairment trial by Novartis Pharmaceuticals. Stop reason: OPERATIONAL.

Terminated by Sponsor

Phase II SCN8A Developmental and Epileptic Encephalopathy Syndrome trial by Neurocrine Biosciences. Stop reason: OPERATIONAL.

This study was prematurely terminated due to sponsor decision.

Phase II Amyotrophic Lateral Sclerosis trial by Novartis Pharmaceuticals. Stop reason: SAFETY.

Study terminated after assessment of potential benefit-risk from available data

Phase II Multiple Sclerosis trial by Sanofi. Stop reason: EFFICACY/FUTILITY.

The study was terminated as it did not meet its primary and key secondary endpoints

Phase III Agitation in Patients With Dementia of the Alzheimer's Type trial by Otsuka Pharmaceutical Development & Commercialization, Inc.. Stop reason: OPERATIONAL.

The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.